IN8bio publishes Phase 1 glioblastoma trial data in oncology journal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
- Twilio, Vylor set to join S&P 500 as index reshuffles members
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
July 9, 2026 8:00 AM EDTFirst peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma
Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard of care benchmark, with no dose-limiting toxicities (DLTs)
NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq:... More
